Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9954346 | 0.87 | ALDH1A1 (0.39) | CREBBPALDH1A1HTTPLATMET | |
| SCHEMBL9954533 | 0.80 | KCNA5 (0.42) | CREBBPPLATGABRA1GABRG2GABRB3 | |
| SCHEMBL9953587 | 0.79 | PPARG (0.41) | HTTFAAHHPGDNPBWR1 | |
| SCHEMBL9954004 | 0.76 | RAB9A (0.51) | CREBBPALDH1A1HTTFAAHP2RX7 | |
| SCHEMBL10036282 | 0.76 | RAB9A (0.51) | CREBBPALDH1A1HTTFAAHP2RX7 | |
| SCHEMBL9953649 | 0.76 | RAB9A (0.51) | CREBBPALDH1A1HTTFAAHP2RX7 | |
| SCHEMBL9954364 | 0.76 | ATM (0.42) | CREBBPALDH1A1METFAAHKAT2B | |
| SCHEMBL4758468 | 0.70 | KMT2A (0.43) | ALDH1A1HTTHPGD | |
| SCHEMBL9954288 | 0.69 | OPRM1 (0.42) | CREBBPALDH1A1PLATGABRA1GABRG2 | |
| SCHEMBL15305627 | 0.69 | PTGS2 (0.48) | CREBBPMETFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654752-B1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PF MEDICAMENT (FR) | 2015-05-27 | — | — | EP | disclosed |
| US-8993569-B2 | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | PIERRE FABRE MEDICAMENT (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2654752-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | Pierre Fabre Medicament (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012085001-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | KCNA4, KCNK4, KCNQ4 | CREBBP 4462/4885MCL1 694/4885ALDH1A1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.